BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology 2017;27:773-81. [DOI: 10.1016/j.euroneuro.2017.05.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Curr Med Res Opin 2020;36:875-82. [PMID: 31990207 DOI: 10.1080/03007995.2020.1723072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study. Int Clin Psychopharmacol 2020;35:305-12. [PMID: 32784346 DOI: 10.1097/YIC.0000000000000326] [Reference Citation Analysis]
3 Yang L, Wu Z, Cao L, Wang Y, Su Y, Huang J, Fang M, Yao Z, Wang Z, Wang F, Zhu Y, Wang Y, Chen J, Peng D, Fang Y. Predictors and moderators of quality of life in patients with major depressive disorder: An AGTs-MDD study report. J Psychiatr Res 2021;138:96-102. [PMID: 33838579 DOI: 10.1016/j.jpsychires.2021.03.063] [Reference Citation Analysis]
4 González Cautela BV, Quintana GR, Akerman J, Pfaus JG. Acute caffeine reverses the disruptive effects of chronic fluoxetine on the sexual behavior of female and male rats. Psychopharmacology (Berl) 2021;238:755-64. [PMID: 33242109 DOI: 10.1007/s00213-020-05728-0] [Reference Citation Analysis]
5 Han X, Wu H, Yin P, Chen Z, Cao X, Duan Y, Xu J, Lao L, Xu S. Electroacupuncture restores hippocampal synaptic plasticity via modulation of 5-HT receptors in a rat model of depression. Brain Research Bulletin 2018;139:256-62. [DOI: 10.1016/j.brainresbull.2018.03.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
6 Sharp T, Barnes NM. Central 5-HT receptors and their function; present and future. Neuropharmacology 2020;177:108155. [PMID: 32522572 DOI: 10.1016/j.neuropharm.2020.108155] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
7 Sun B, Lv Y, Xu H, Qi C, Li C, Liu P. Effects of Vortioxetine on depression model rats and expression of BDNF and Trk B in hippocampus. Exp Ther Med 2020;20:2895-902. [PMID: 32765787 DOI: 10.3892/etm.2020.9026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kranaster L, Jennen-Steinmetz C, Sartorius A. A novel seizure quality index based on ictal parameters for optimizing clinical decision-making in electroconvulsive therapy. Part 2: Validation. Eur Arch Psychiatry Clin Neurosci 2019;269:859-65. [PMID: 30535616 DOI: 10.1007/s00406-018-0962-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
9 Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]